Dr. Chadi Nabhan delves into the realm of artificial intelligence (AI) and its transformative impact on drug development with Adam Petrich, MD, chief medical officer of QuantHealth. Dr. Petrich discusses the AI solutions crafted by QuantHealth, which are aimed at simulating and predicting clinical trial outcomes to enhance success rates.
Advertisement
The addition of dostarlimab to platinum chemotherapy is cost effective and improves QoL.
Research has begun to question recommendations to restrict potassium with CKD to manage hyperkalemia.
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
This marks the first FDA approval of a radioactive drug for patients 12 years or older with SSTER-positive GEP-NETs.
Will sparsentan prove a winner for patients with FSGS, or are we doomed to forever treat them with Acthar Gel?
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Townsend details the science behind aldosterone, the hormone that regulates sodium and helps regulate blood pressure.
Dr. Townsend discusses hypertension and how not adhering to medications is the biggest issue for patients.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Surgical resection with curative intent is the primary therapy for gastric cancer, yet the 5-year survival rate is just 20%.
This marks the first FDA approval of a radioactive drug for patients 12 years or older with SSTER-positive GEP-NETs.
TOPAZ-1's 3-year follow-up is the longest survival follow-up for a global, randomized phase III trial in this setting.
The prognostic value of the Edmonton Symptom Assessment Scale in patients with gastroesophageal cancer was investigated.
A study compared the long-term survival outcomes of endoscopic and surgical treatment for GISTs ranging from 5 to 10 cm.
Researchers also found statistical significance for the TBR SULpeak of the primary and liver lesions.
The Latest From Heme Today
Etavopivat was safe and increased hemoglobin, decreased hemolysis, and improved red blood cells in patients with SCD.
Dr. Vadivelan shared her study on pituitary and pancreatic iron deposition in patients with SCD at the 2024 ASPHO Conference.
Stuart Orkin, MD, has been named as one of Time’s 100 Most Influential People of 2024 for his work in hemoglobin research.
The study compared health care resource use and costs of pediatric patients with SCD compared with matched controls.
Intravenous iron was safe and effective in pediatric patients with iron deficiency anemia and inflammatory bowel disease.
Delaying treatment for SAA until genetic testing for IBMFS may be detrimental in patients with negative workup and history.
